BLAINTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDERPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
27
Data completeness
7/8 — Comprehensive
Priority Review
BESPONSA (inotuzumab ozogamicin) by Pfizer is cd22-directed antibody interactions [moa]. Approved for acute lymphoblastic leukemia. First approved in 2017.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BESPONSA (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate that delivers a cytotoxic payload to B-cell malignancies. It is approved for acute lymphoblastic leukemia and B-cell lymphomas. The drug works by binding CD22 on tumor cells and delivering intracellular toxin to induce cell death.
$0.002BPart D
PeakBESPONSA is in peak lifecycle stage with modest Part D spending ($2M, 19 claims in 2023), indicating a niche product with stable but limited market penetration in hematologic malignancies.
Mechanism of Action
CD22-directed Antibody Interactions
Pharmacologic Class:
CD22-directed Immunoconjugate
Indications (1)
Clinical Trials (27)
A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.
Started Nov 2024
10 enrolled
Acute Lymphocytic Leukemia
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Started Jun 2023
68 enrolled
B Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Started May 2023
100 enrolled
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
Started Mar 2023
32 enrolled
Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Started Feb 2023
44 enrolled
Acute Lymphoblastic Leukemia
Worked on BESPONSA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.